Proven across oncology's most complex modalities.

We grasp the intricacies of oncology studies, from the ever-changing regulatory landscape and novel study designs to personalized treatment options.

Specialized expertise in managing adverse events and treatment-related toxicities, including:

• ►Cancer breakthrough pain
• ►Cancer cachexia
• ►Chemotherapy-induced toxicities
• ►Tumor Lysis Syndrome
• ►Immune-related Adverse Events (irAEs)
• ►Cell & Gene Therapy toxicities (CRS, ICANS)

Our team has successfully advanced over 210 rare disease studies with nearly 19,500 patients across more than 2,900 sites worldwide.

We address every challenge head-on, from designing protocols with appropriate inclusion/exclusion criteria to finding eligible patients in sparse populations and securing experienced sites.

We have a dedicated focus on the unique needs of pediatric trials. We carefully examine the pediatric patient journey to balance ease of participation for children and their caregivers with the requirement to collect high-quality data.

We leverage technology and our established relationships with KOLs and patient advocacy groups to find patients. We reduce patient burden through patient-centric practices to maximize retention.

Our leadership team has direct clinical development and BLA filing experience with approved CAR-T cell therapies, including playing a key role in the approval of AUCATZYL® (Obe-cel).

Expert site guidance is critical for cell or gene therapies. We ensure sites can effectively handle complex study execution, logistics, and patient monitoring from leukapheresis to post-infusion follow-up.

Deep expertise in monitoring and managing the unique toxicities associated with cell therapies, such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).